4.0 Central Nervous System

Contents

• 4.1 Hypnotics and anxiolytics
  • 4.1.1 Hypnotics
  • 4.1.2 Anxiolytics
    • 4.1.2.1 Acute anxiety state
    • 4.1.2.2 Anxiety disorders
  • 4.1.3 Barbiturates
• 4.2 Drugs used in psychoses and related disorders
  • 4.2.1 Antipsychotic drugs
    • 4.2.1.1 Management of agitation and aggression
  • 4.2.3 Mood stabilising drugs
    • 4.2.3.1 Treatment of the acute phase of mania
    • 4.2.3.2 Maintenance treatment of bipolar disorder with mood stabilisers
• 4.3 Antidepressant drugs
  • 4.3.1 Mild, moderate and severe depression
  • 4.3.2 Antidepressants for the treatment of anxiety disorders*
    • 4.3.2.1 Generalised anxiety disorder (GAD), social anxiety disorder
    • 4.3.2.2 Panic disorder
    • 4.3.2.3 Post-traumatic stress disorder
    • 4.3.2.4 Obsessive compulsive disorder
• 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
  • 4.4.1 Narcolepsy
  • 4.4.2 Attention deficit hyperactive disorder (ADHD) in adults
• 4.5 Drugs used in the treatment of obesity
  • 4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract
  • 4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract
• 4.6 Drugs used in nausea and vertigo
  • 4.6.1 Drugs for the short-term treatment of nausea and vomiting
    • 4.6.1.1 Motion sickness
  • 4.6.2 Vertigo
• 4.7 Analgesics
  • 4.7.1 General management of acute pain
    • 4.7.1.1 Non-opioid & compound analgesics
    • 4.7.1.2 Opioid analgesics
  • 4.7.2 Chronic non-malignant pain
  • 4.7.3 Neuropathic pain
  • 4.7.4 Antimigraine drugs
    • 4.7.4.1 Treatment of acute migraine attack
    • 4.7.4.2 Migraine prophylaxis
    • 4.7.4.3 Drug treatment of cluster headache
• 4.8 Anti-epileptics
  • 4.8.1 Control of epilepsy
  • 4.8.2 Drugs used in status epilepticus
• 4.9 Drugs used in parkinsonism and related disorders
  • 4.9.1 Dopaminergic drugs used in parkinsonism
    • 4.9.1.1 Dopamine receptor agonists
    • 4.9.1.2 Levodopa
    • 4.9.1.3 Monoamine-oxidase-B (MAOB) inhibitors
    • 4.9.1.4 Catechol-O-methyltransferase inhibitors (COMT inhibitors)
  • 4.9.2 Antimuscarinic drugs used in parkinsonism
  • 4.9.3 Essential tremor
  • 4.9.4 Management of dementia in Parkinson’s disease
• 4.10 Medications used in substance use disorders
  • 4.10.1 Opioid maintenance prescribing
  • 4.10.2 Opioid detoxification
  • 4.10.3 Benzodiazepine and Z drug withdrawal
  • 4.10.4 Alcohol dependence
    • 4.10.4.1 Acute alcohol withdrawal
    • 4.10.4.2 Relapse Prevention
    • 4.10.4.3 Interventions for the reduction of alcohol consumption
    • 4.10.4.4 Vitamin supplementation
  • 4.10.5 Cigarette smoking
• 4.11 Drugs for dementia
  • 4.11.1 Management of Behavioural and Psychological Symptoms of Dementia (BPSD)